- Home
- Publications
- Publication Search
- Publication Details
Title
PI3-Kinase Inhibitors in Chronic Lymphocytic Leukemia
Authors
Keywords
New targets, PI3K, PI3K delta, PI3K-δ, PI3K Gamma, PI3K-γ, CAL-101, GS-1101, Idelalisib, INK-1197, IPI-145, Chronic lymphocytic leukemia, Small lymphocytic lymphoma
Journal
Current Hematologic Malignancy Reports
Volume 9, Issue 1, Pages 33-43
Publisher
Springer Nature
Online
2014-01-06
DOI
10.1007/s11899-013-0189-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Isoform-Specific Functions of Phosphoinositide 3-Kinases: p110 but Not p110 Promotes Optimal Allergic Responses In Vivo
- (2014) K. Ali et al. JOURNAL OF IMMUNOLOGY
- Signaling by the Phosphoinositide 3-Kinase Family in Immune Cells
- (2013) Klaus Okkenhaug Annual Review of Immunology
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- (2013) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibitors of B-Cell Receptor Signaling for Patients With B-Cell Malignancies
- (2012) Michael Y. Choi et al. CANCER JOURNAL
- Novel Targeted Agents and the Need to Refine Clinical End Points in Chronic Lymphocytic Leukemia
- (2012) Bruce D. Cheson et al. JOURNAL OF CLINICAL ONCOLOGY
- GS-1101: A Delta-Specific PI3K Inhibitor in Chronic Lymphocytic Leukemia
- (2012) Ines M. Macias-Perez et al. Current Hematologic Malignancy Reports
- Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network
- (2011) A Smith et al. BRITISH JOURNAL OF CANCER
- Receptor Tyrosine Kinases and TLR/IL1Rs Unexpectedly Activate Myeloid Cell PI3Kγ, A Single Convergent Point Promoting Tumor Inflammation and Progression
- (2011) Michael C. Schmid et al. CANCER CELL
- Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group
- (2011) Kirsten Fischer et al. JOURNAL OF CLINICAL ONCOLOGY
- Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-hodgkin lymphoma
- (2010) Trevor W. Dennie et al. CLINICAL THERAPEUTICS
- Ofatumumab, a Novel Anti-CD20 Monoclonal Antibody for the Treatment of B-Cell Malignancies
- (2010) Bruce D. Cheson JOURNAL OF CLINICAL ONCOLOGY
- Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
- (2010) M Hallek et al. LANCET
- The emerging mechanisms of isoform-specific PI3K signalling
- (2010) Bart Vanhaesebroeck et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
- (2009) J. W. Friedberg et al. BLOOD
- Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group
- (2009) Stephan Stilgenbauer et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Randomized Study of Bendamustine Compared With Chlorambucil in Previously Untreated Patients With Chronic Lymphocytic Leukemia
- (2009) Wolfgang U. Knauf et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now